clinical trial · NCT05657691
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Actinogen Medical·phase2·completed·n = 167
Major Depressive DisorderMDDCognitive ImpairmentXanamem™Placebo
brief summary
Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamem™ in treating patients with cognitive and depressive symptoms. Trial participants will be randomized to either receive 10mg of Xanamem™ once daily or a Placebo at a 1:1 ratio in a double-blinded fashion.
started
Nov 28, 2022
primary completion
Jul 1, 2024
completion
Jul 1, 2024
last updated
Jan 22, 2025
official title
XanaCIDD: A Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol